Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780)

Zhiping Gu, Richard Y. Lee, Todd Skaar, Kerrie B. Bouker, James N. Welch, Jianping Lu, Aiyi Liu, Yuelin Zhu, Natalie Davis, Fabio Leonessa, Nils Brünner, Yue Wang, Robert Clarke

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

To identify genes associated with survival from antiestrogens, both serial analysis of gene expression and gene expression microarrays were used to explore the transcriptomes of antiestrogen-responsive (MCF7/LCC1) and -resistant variants (MCF7/LCC9) of the MCF-7 human breast cancer cell line. Structure of the gene microarray expression data was visualized at the top level using a novel algorithm that derives the first three principal components, fitted to the antiestrogen-resistant and -responsive gene expression data, from Fisher's information matrix. The differential regulation of several candidate genes was confirmed. Functional studies of the basal expression and endocrine regulation of transcriptional activation of implicated transcription factors were studied using promoter-reporter assays. The putative tumor suppressor interferon regulatory factor-1 is down-regulated in resistant cells, whereas its nucleolar phosphoprotein inhibitor nucleophosmin is up-regulated. Resistant cells also up-regulate the transcriptional activation of cyclic AMP response element (CRE) binding and nuclear factor κB (NFκB) while down-regulating epidermal growth factor receptor protein expression. Inhibition of NFκB activity by ICI 182,780 is lost in resistant cells, but CRE activity is not regulated by ICI 182,780 in either responsive or resistant cells. Parthenolide, a potent and specific inhibitor of NFκB, inhibits the anchorage-dependent proliferation of antiestrogen-resistant but not antiestrogen-responsive cells. This observation implies a greater reliance on their increased NFκB signaling for proliferation in cells that have survived prolonged exposure to ICI 182,780. These data from serial analysis of gene expression and gene microarray studies implicate changes in a novel signaling pathway, involving interferon regulatory factor-1, nucleophosmin, NFκB, and CRE binding in cell survival after antiestrogen exposure. Cells can up-regulate some estrogen-responsive genes while concurrently losing the ability of antiestrogens to regulate their expression. Signaling pathways that are not regulated by estrogens also can be up-regulated. Thus, some breast cancer cells may survive antiestrogen treatment by bypassing specific growth inhibitory signals induced by antagonist-occupied estrogen receptors.

Original languageEnglish (US)
Pages (from-to)3428-3437
Number of pages10
JournalCancer Research
Volume62
Issue number12
StatePublished - Jun 15 2002
Externally publishedYes

Fingerprint

Interferon Regulatory Factor-1
Estrogen Receptor Modulators
Response Elements
Cyclic AMP
Gene Expression
Transcriptional Activation
Genes
Estrogens
Up-Regulation
Breast Neoplasms
fulvestrant
nucleophosmin
Phosphoproteins
Transcriptome
Epidermal Growth Factor Receptor
Cell Survival
Transcription Factors
Cell Proliferation
Cell Line
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). / Gu, Zhiping; Lee, Richard Y.; Skaar, Todd; Bouker, Kerrie B.; Welch, James N.; Lu, Jianping; Liu, Aiyi; Zhu, Yuelin; Davis, Natalie; Leonessa, Fabio; Brünner, Nils; Wang, Yue; Clarke, Robert.

In: Cancer Research, Vol. 62, No. 12, 15.06.2002, p. 3428-3437.

Research output: Contribution to journalArticle

Gu, Z, Lee, RY, Skaar, T, Bouker, KB, Welch, JN, Lu, J, Liu, A, Zhu, Y, Davis, N, Leonessa, F, Brünner, N, Wang, Y & Clarke, R 2002, 'Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780)', Cancer Research, vol. 62, no. 12, pp. 3428-3437.
Gu, Zhiping ; Lee, Richard Y. ; Skaar, Todd ; Bouker, Kerrie B. ; Welch, James N. ; Lu, Jianping ; Liu, Aiyi ; Zhu, Yuelin ; Davis, Natalie ; Leonessa, Fabio ; Brünner, Nils ; Wang, Yue ; Clarke, Robert. / Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). In: Cancer Research. 2002 ; Vol. 62, No. 12. pp. 3428-3437.
@article{a6b9aeb507544b539a5c4f42db3390a5,
title = "Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780)",
abstract = "To identify genes associated with survival from antiestrogens, both serial analysis of gene expression and gene expression microarrays were used to explore the transcriptomes of antiestrogen-responsive (MCF7/LCC1) and -resistant variants (MCF7/LCC9) of the MCF-7 human breast cancer cell line. Structure of the gene microarray expression data was visualized at the top level using a novel algorithm that derives the first three principal components, fitted to the antiestrogen-resistant and -responsive gene expression data, from Fisher's information matrix. The differential regulation of several candidate genes was confirmed. Functional studies of the basal expression and endocrine regulation of transcriptional activation of implicated transcription factors were studied using promoter-reporter assays. The putative tumor suppressor interferon regulatory factor-1 is down-regulated in resistant cells, whereas its nucleolar phosphoprotein inhibitor nucleophosmin is up-regulated. Resistant cells also up-regulate the transcriptional activation of cyclic AMP response element (CRE) binding and nuclear factor κB (NFκB) while down-regulating epidermal growth factor receptor protein expression. Inhibition of NFκB activity by ICI 182,780 is lost in resistant cells, but CRE activity is not regulated by ICI 182,780 in either responsive or resistant cells. Parthenolide, a potent and specific inhibitor of NFκB, inhibits the anchorage-dependent proliferation of antiestrogen-resistant but not antiestrogen-responsive cells. This observation implies a greater reliance on their increased NFκB signaling for proliferation in cells that have survived prolonged exposure to ICI 182,780. These data from serial analysis of gene expression and gene microarray studies implicate changes in a novel signaling pathway, involving interferon regulatory factor-1, nucleophosmin, NFκB, and CRE binding in cell survival after antiestrogen exposure. Cells can up-regulate some estrogen-responsive genes while concurrently losing the ability of antiestrogens to regulate their expression. Signaling pathways that are not regulated by estrogens also can be up-regulated. Thus, some breast cancer cells may survive antiestrogen treatment by bypassing specific growth inhibitory signals induced by antagonist-occupied estrogen receptors.",
author = "Zhiping Gu and Lee, {Richard Y.} and Todd Skaar and Bouker, {Kerrie B.} and Welch, {James N.} and Jianping Lu and Aiyi Liu and Yuelin Zhu and Natalie Davis and Fabio Leonessa and Nils Br{\"u}nner and Yue Wang and Robert Clarke",
year = "2002",
month = "6",
day = "15",
language = "English (US)",
volume = "62",
pages = "3428--3437",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780)

AU - Gu, Zhiping

AU - Lee, Richard Y.

AU - Skaar, Todd

AU - Bouker, Kerrie B.

AU - Welch, James N.

AU - Lu, Jianping

AU - Liu, Aiyi

AU - Zhu, Yuelin

AU - Davis, Natalie

AU - Leonessa, Fabio

AU - Brünner, Nils

AU - Wang, Yue

AU - Clarke, Robert

PY - 2002/6/15

Y1 - 2002/6/15

N2 - To identify genes associated with survival from antiestrogens, both serial analysis of gene expression and gene expression microarrays were used to explore the transcriptomes of antiestrogen-responsive (MCF7/LCC1) and -resistant variants (MCF7/LCC9) of the MCF-7 human breast cancer cell line. Structure of the gene microarray expression data was visualized at the top level using a novel algorithm that derives the first three principal components, fitted to the antiestrogen-resistant and -responsive gene expression data, from Fisher's information matrix. The differential regulation of several candidate genes was confirmed. Functional studies of the basal expression and endocrine regulation of transcriptional activation of implicated transcription factors were studied using promoter-reporter assays. The putative tumor suppressor interferon regulatory factor-1 is down-regulated in resistant cells, whereas its nucleolar phosphoprotein inhibitor nucleophosmin is up-regulated. Resistant cells also up-regulate the transcriptional activation of cyclic AMP response element (CRE) binding and nuclear factor κB (NFκB) while down-regulating epidermal growth factor receptor protein expression. Inhibition of NFκB activity by ICI 182,780 is lost in resistant cells, but CRE activity is not regulated by ICI 182,780 in either responsive or resistant cells. Parthenolide, a potent and specific inhibitor of NFκB, inhibits the anchorage-dependent proliferation of antiestrogen-resistant but not antiestrogen-responsive cells. This observation implies a greater reliance on their increased NFκB signaling for proliferation in cells that have survived prolonged exposure to ICI 182,780. These data from serial analysis of gene expression and gene microarray studies implicate changes in a novel signaling pathway, involving interferon regulatory factor-1, nucleophosmin, NFκB, and CRE binding in cell survival after antiestrogen exposure. Cells can up-regulate some estrogen-responsive genes while concurrently losing the ability of antiestrogens to regulate their expression. Signaling pathways that are not regulated by estrogens also can be up-regulated. Thus, some breast cancer cells may survive antiestrogen treatment by bypassing specific growth inhibitory signals induced by antagonist-occupied estrogen receptors.

AB - To identify genes associated with survival from antiestrogens, both serial analysis of gene expression and gene expression microarrays were used to explore the transcriptomes of antiestrogen-responsive (MCF7/LCC1) and -resistant variants (MCF7/LCC9) of the MCF-7 human breast cancer cell line. Structure of the gene microarray expression data was visualized at the top level using a novel algorithm that derives the first three principal components, fitted to the antiestrogen-resistant and -responsive gene expression data, from Fisher's information matrix. The differential regulation of several candidate genes was confirmed. Functional studies of the basal expression and endocrine regulation of transcriptional activation of implicated transcription factors were studied using promoter-reporter assays. The putative tumor suppressor interferon regulatory factor-1 is down-regulated in resistant cells, whereas its nucleolar phosphoprotein inhibitor nucleophosmin is up-regulated. Resistant cells also up-regulate the transcriptional activation of cyclic AMP response element (CRE) binding and nuclear factor κB (NFκB) while down-regulating epidermal growth factor receptor protein expression. Inhibition of NFκB activity by ICI 182,780 is lost in resistant cells, but CRE activity is not regulated by ICI 182,780 in either responsive or resistant cells. Parthenolide, a potent and specific inhibitor of NFκB, inhibits the anchorage-dependent proliferation of antiestrogen-resistant but not antiestrogen-responsive cells. This observation implies a greater reliance on their increased NFκB signaling for proliferation in cells that have survived prolonged exposure to ICI 182,780. These data from serial analysis of gene expression and gene microarray studies implicate changes in a novel signaling pathway, involving interferon regulatory factor-1, nucleophosmin, NFκB, and CRE binding in cell survival after antiestrogen exposure. Cells can up-regulate some estrogen-responsive genes while concurrently losing the ability of antiestrogens to regulate their expression. Signaling pathways that are not regulated by estrogens also can be up-regulated. Thus, some breast cancer cells may survive antiestrogen treatment by bypassing specific growth inhibitory signals induced by antagonist-occupied estrogen receptors.

UR - http://www.scopus.com/inward/record.url?scp=18544396176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18544396176&partnerID=8YFLogxK

M3 - Article

C2 - 12067985

AN - SCOPUS:18544396176

VL - 62

SP - 3428

EP - 3437

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -